Welcome!

News Feed Item

The Global Market for Stem Cells

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Global Market for Stem Cells

 http://www.reportlinker.com/p02274672/The-Global-Market-for-Stem-Cells.html

This BCC Research report provides detailed market, technology, and industry analyses to quantify and qualify the global market for prescription drug products. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018.

Use this report to:
- Quantify and qualify the stem cell research market for prescription drug products.
- Receive information about stem cell technology and its practical applications.
- Understand how the regulatory environment, healthcare policies, demographics, and other factors directly affect the stem cell-related drug market.
- Learn about the nature and structure of the stem cell industry along with profiles of the leading companies.

Highlights
- BCC Research projects that the global stem cell market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 3.6% from 2013 through 2018.
- The Americas is the largest region of global stem cell market, with a market share of about $2.0 billion in 2013. The region is projected to increase to nearly $3.9 billion by 2018, with a CAGR of 13.9% for the period of 2013 to 2018.
- Europe is the second largest segment of the global stem cell market and is expected to grow at a CAGR of 13.4% reaching about $2.4 billion by 2018 from nearly $1.4 billion in 2013.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription drug products.
Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and
considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the stem cell-related drug market.
The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.

REASONS FOR DOING THE STUDY
Although products based on stem cells do not yet form an established market, unlike some other potential applications of bioscience, stem cell technology has already
produced a number of significant products in important therapeutic areas. This is because the possibilities for successful stem cell therapy are almost beyond estimation,
and the urgent need to develop this field is overriding the established, step-by-step approach to proceeding from basic science to practical applications. The potential
scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its practical applications so far, evaluate the participating
companies and look to its future.

SCOPE OF REPORT
This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global
terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2014-dollar value without attempting to predict the effect of inflation/deflation.
Therapeutic categories quantified and forecast include cancer, CNS diseases, infections and cardiovascular. Major country markets in three regions—Americas, Europe and
Asia—are analyzed and forecast, with a summary for the rest of the world.

METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. Primary research includes interviews with leading individuals in stem cell companies
and industry associations. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources
consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically
assessed by BCC Research.

INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management
executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in
marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES
Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also reviewed.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
MARKET ANALYSES AND FORECASTS 2
METHODOLOGY 3
INTENDED AUDIENCE 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 3
BCC RESEARCH WEBSITE 3
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
DEFINITIONS 6
APPLICATIONS 6
RESEARCH AND COMMERCIALIZATION 6
FUNDING 7
MARKET 7
SUMMARY TABLE GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2018
($ MILLIONS) 8
SUMMARY FIGURE GLOBAL STEM CELL MARKET AND FORECASTS, 2012-2018 ($
MILLIONS) 8
CHAPTER 3 OVERVIEW 10
CELLS 10
STEM CELLS 10
FIGURE 1 EARLY DEVELOPMENT OF EMBRYO 10
INDUCED PLURIPOTENT STEM CELLS 13
hpSCS 14
THE CANCER PROBLEM 15
CANCER STEM CELLS-A WIDER TOPIC 15
CHAPTER 4 STEM CELL RESEARCH 19
HISTORY 19
EMBRYONIC STEM CELLS 20
Growth and Identification of ESCs 20
Stimulating ESCs to Differentiate 21
NEW CELL LINE 21
ADULT STEM CELLS 22
Mesenchymal Stem Cells (MSCs) 22
Haematopoietic Stem Cells (HSCs) 23
Neural Stem Cells (NSCs) 23
Endothelial Progenitor Cells (EPCs) 23
Epithelial Stem Cells (ESCs) 23
Very Small Embryonic-Like Cells (VSELs) 23
CORD BLOOD STEM CELLS 23
INDUCED PLURIPOTENT STEM CELLS (IPSCS) 24
Nuclear Reprogramming 24
CELL-BASED THERAPEUTICS 25
EMBRYONIC-DERIVED STEM CELLS 25
ADULT/PROGENITOR-DERIVED STEM CELLS 26
ENGINEERED SCS FOR TRANSPLANTATION 26
THERAPEUTIC STEM CELL BANKING 27
STEM CELL-BASED BIOMEDICAL RESEARCH 28
TABLE 1 STEM CELL RESEARCH CENTERS 28
REGULATION OF STEM CELL RESEARCH 30
AUSTRALIA 30
BRAZIL 31
CANADA 31
CHINA 31
FRANCE 31
GERMANY 32
INDIA 32
IRELAND 32
ISRAEL 33
ITALY 33
JAPAN 33
SOUTH KOREA 33
SPAIN 33
SWEDEN 34
UNITED KINGDOM 34
UNITED STATES 34
California 34
Massachusetts 35
Michigan 35
New Jersey 35
New York 35
FDA APPROACH 35
EUROPEAN UNION 35
PRACTICALITIES OF STEM CELL RESEARCH AND PRODUCTION 36
STEM CELL PRODUCTION 36
STEM CELL ACQUISITION 37
Characterization and Expansion 37
Maintenance and Storage 38
STEM CELL PRODUCTION ECONOMICS 39
Customized Therapy 39
Banks 40
NOVEL STEM CELL PRODUCTION DEVELOPMENTS 40
ISOLATION AND ENGINEERING 41
Adult Stem Cells 41
Embryonic Stem Cells 42
Induced Pluripotent Stem Cells 43
STEM CELL BANKING 44
ISCBI PROJECT 44
TABLE 2 COUNTRIES ENGAGED IN THE ISCBI PROGRAM 45
CHAPTER 5 STEM CELL APPLICATIONS 48
REGENERATIVE MEDICINE 48
CURRENT APPLICATIONS OF STEM CELL THERAPY 51
CANCER 51
Hematopoiesis (Blood Cell Formation) 51
AMYOTROPHIC LATERAL SCLEROSIS 52
PARKINSON'S DISEASE 53
SPINAL CORD INJURY 54
ALZHEIMER'S DISEASE 56
STROKE 57
HEART DISEASE 59
Doubts Expressed 61
PERIPHERAL ARTERIAL DISEASE 61
TYPE 1 DIABETES 63
ORTHOPEDIC REPAIR 64
LIVER FAILURE 65
GRAFT-VERSUS-HOST DISEASE 66
LUNG DISEASE 67
STATUS OF STEM CELL CLINICAL TRIALS 67
Prochymal-stem Cell Therapy 68
Prochymal-Crohn's Disease and Gastrointestinal Injury from
Radiation 68
Mesenchymal Precursor Cell (MPC) Product—Stem Cell Therapy
(Orphan Drug) 68
MyoCell-Stem Cell Therapy 69
ixmyelocel-T-Stem Cell Therapy (Fast Track) 69
StemEx (carlecortemcel-L)—Stem Cell Therapy (Orphan Drug) (Fast
Track) 69
GSK 2696273-Stem Cell Therapy 70
Adult Autologous Stem Cell Therapy (Renew)—Stem Cell Therapy 70
CHAPTER 6 STEM CELL PATENTS 73
GENERAL BACKGROUND ON PATENTS 73
STEM CELL PATENTS 74
PATENTABILITY OF STEM CELL LINES 74
INDIVIDUAL COUNTRY POLICIES 75
UNITED STATES 75
CANADA 75
EPC 75
UNITED KINGDOM 75
GERMANY 76
JAPAN 76
CHINA 76
iPS Cells 76
TABLE 3 IPS-RELATED PATENTS (YAMANAKA, 2011) 77
TABLE 4 CLASSIFICATION OF STEM CELL PATENTS 78
CHAPTER 7 STEM CELL MARKETS 80
MARKETS FOR STEM CELLS 80
MARKET DRIVERS 80
Healthcare 80
TABLE 5 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES 82
Biotechnology 83
Pharmaceutical 84
MARKET OPPORTUNITIES BY THERAPEUTIC CLASS 85
CANCER 85
Other Cancers 86
CARDIOVASCULAR DISEASE 86
Myocardial Infarction 88
TABLE 6 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD 89
CENTRAL NERVOUS SYSTEM DISEASE 89
Spinal Cord Injury (SCI) 90
TABLE 7 STATISTICS FOR SCI WORLDWIDE, 2011 90
Neurodegenerative Diseases 91
TABLE 8 NEURODEGENERATIVE DISEASES WORLDWIDE, 2011 (MILLIONS) 91
DIABETES MELLITUS 92
TABLE 9 STATISTICS FOR DIABETES IN THE U.S., 2014 92
TABLE 10 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES,
THROUGH 2018 ($ BILLIONS) 93
SKELETAL SYSTEM 94
GLOBAL MARKET ESTIMATES AND FORECASTS 95
TABLE 11 GLOBAL STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
REGIONAL AND NATIONAL MARKET ANALYSIS 95
AMERICAS 95
TABLE 12 AMERICAS STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
U.S. 96
TABLE 13 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES 96
TABLE 14 THE U.S. STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 97
TABLE 15 THE U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 98
TABLE 16 THE U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 98
Canada 98
TABLE 17 CANADA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 99
TABLE 18 CANADA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 99
TABLE 19 CANADA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 100
Brazil 100
TABLE 20 BRAZIL'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 101
TABLE 21 BRAZIL'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 101
TABLE 22 BRAZIL'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 101
Mexico 102
TABLE 23 MEXICO'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 102
TABLE 24 MEXICO'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 102
EUROPE 103
TABLE 25 EUROPEAN STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 103
Market Opportunities by Disease Category 104
TABLE 26 STATISTICS FOR CVD IN EUROPE, 2012 104
TABLE 27 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN
COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES) 104
TABLE 28 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013 105
TABLE 29 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT
EUROPEAN COUNTRIES, 2011 105
TABLE 30 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN
COUNTRIES, 2013 106
France 106
TABLE 31 FRANCE'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 106
TABLE 32 FRANCE'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 106
TABLE 33 FRANCE'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 107
Germany 107
TABLE 34 GERMANY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 107
TABLE 35 GERMANY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 108
TABLE 36 GERMANY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 108
Italy 108
TABLE 37 ITALY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 109
TABLE 38 ITALY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 109
TABLE 39 ITALY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 109
Spain 109
TABLE 40 SPAIN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 111
TABLE 41 SPAIN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 111
TABLE 42 SPAIN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 111
United Kingdom 111
TABLE 43 U.K.'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 112
TABLE 44 U.K.'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 112
TABLE 45 U.K.'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 113
ASIA 113
Market Opportunities by Disease Category 113
TABLE 46 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011 113
TABLE 47 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES 114
TABLE 48 ASIA'S STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 114
Japan 114
TABLE 49 JAPAN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 116
TABLE 50 JAPAN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 116
TABLE 51 JAPAN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 116
China 116
TABLE 52 CHINA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 119
TABLE 53 CHINA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 120
TABLE 54 CHINA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 120
India 120
TABLE 55 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA 121
TABLE 56 INDIA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 121
TABLE 57 INDIA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 122
TABLE 58 INDIA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 122
REST OF WORLD 122
TABLE 59 REST OF WORLD STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 122
CHAPTER 8 COMPANY PROFILES 124
3DM 125
AASTROM BIOSCIENCES INC. 125
ADVANCED CELL TECHNOLOGY INC. 126
ALDAGEN INC. 127
ANGIOBLAST SYSTEMS 127
ARTERIOCYTE 128
ATHERSYS INC. 128
BEIKE BIOTECHNOLOGY CO., LTD. 129
BIOHEART INC. 130
BIOTIME INC. 131
BRAINSTORM CELL THERAPEUTICS INC. 132
CAPRICOR INC. 133
CARDIO3 BIOSCIENCES S.A. 134
CELLARTIS AB 135
CELLERANT THERAPEUTICS INC. 136
CELLERIX SA 137
CELLULAR DYNAMICS INTERNATIONAL 138
CYTORI THERAPEUTICS INC. 138
EPISTEM LTD. 140
FORTICELL BIOSCIENCE INC. 140
GAMIDA CELL, LTD. 141
GLOBALSTEM 142
HYBRID ORGAN GMBH 143
INTELLICELL BIOSCIENCES INC. 143
INTERNATIONAL STEM CELL CORP. 144
JUVENTAS THERAPEUTICS INC. 145
MEDISTEM INC. 146
MESOBLAST LTD. 147
NEOSTEM INC. 148
NEURALSTEM 149
NEUROGENERATION 149
OSIRIS THERAPEUTICS INC. 150
PHARMASTEM THERAPEUTICS INC. 151
PLUREON CORP. 151
PRIMEGEN BIOTECH LLC 151
RENEURON GROUP 152
RHINOCYTE INC. 153
STEM CELLS INC. 153
STEMCELL TECHNOLOGIES SARL 154
STEM CELL THERAPEUTICS CORP. 155
STEMEDICA CELL TECHNOLOGIES INC. 156
STEMINA BIOMARKER DISCOVERY INC. 156
STEMPEUTICS RESEARCH PVT. LTD. 157
TIGENIX NV 158
TRISTEM CORP. 159
VERASTEM INC. 160
VERISTEM TECHNOLOGIES 160
VIACYTE 161
VITRO DIAGNOSTICS INC. 162
WICELL RESEARCH INSTITUTE 162
XPAND BIOTECHNOLOGY BV 163
CHAPTER 9 APPENDIX 1: GLOSSARY 165
CHAPTER 10 APPENDIX 2: SIGNIFICANT STEM CELL RESEARCH PATENTS 172
TABLE 60 SIGNIFICANT STEM CELL RESEARCH PATENTS 172

LIST OF TABLES

SUMMARY TABLE GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2018 ($
MILLIONS) 8
TABLE 1 STEM CELL RESEARCH CENTERS 28
TABLE 2 COUNTRIES ENGAGED IN THE ISCBI PROGRAM 45
TABLE 3 IPS-RELATED PATENTS (YAMANAKA, 2011) 77
TABLE 4 CLASSIFICATION OF STEM CELL PATENTS 78
TABLE 5 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES 82
TABLE 6 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD 89
TABLE 7 STATISTICS FOR SCI WORLDWIDE, 2011 90
TABLE 8 NEURODEGENERATIVE DISEASES WORLDWIDE, 2011 (MILLIONS) 91
TABLE 9 STATISTICS FOR DIABETES IN THE U.S., 2014 92
TABLE 10 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES,
THROUGH 2018 ($ BILLIONS) 93
TABLE 11 GLOBAL STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
TABLE 12 AMERICAS STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
TABLE 13 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES 96
TABLE 14 THE U.S. STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 97
TABLE 15 THE U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 98
TABLE 16 THE U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 98
TABLE 17 CANADA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 99
TABLE 18 CANADA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 99
TABLE 19 CANADA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 100
TABLE 20 BRAZIL'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 101
TABLE 21 BRAZIL'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 101
TABLE 22 BRAZIL'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 101
TABLE 23 MEXICO'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 102
TABLE 24 MEXICO'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 102
TABLE 25 EUROPEAN STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 103
TABLE 26 STATISTICS FOR CVD IN EUROPE, 2012 104
TABLE 27 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN
COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES) 104
TABLE 28 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013 105
TABLE 29 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT EUROPEAN
COUNTRIES, 2011 105
TABLE 30 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN
COUNTRIES, 2013 106
TABLE 31 FRANCE'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 106
TABLE 32 FRANCE'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 106
TABLE 33 FRANCE'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 107
TABLE 34 GERMANY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 107
TABLE 35 GERMANY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 108
TABLE 36 GERMANY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 108
TABLE 37 ITALY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 109
TABLE 38 ITALY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 109
TABLE 39 ITALY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 109
TABLE 40 SPAIN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 111
TABLE 41 SPAIN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 111
TABLE 42 SPAIN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 111
TABLE 43 U.K.'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 112
TABLE 44 U.K.'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 112
TABLE 45 U.K.'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 113
TABLE 46 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011 113
TABLE 47 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES 114
TABLE 48 ASIA'S STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 114
TABLE 49 JAPAN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 116
TABLE 50 JAPAN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 116
TABLE 51 JAPAN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 116
TABLE 52 CHINA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 119
TABLE 53 CHINA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 120
TABLE 54 CHINA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 120
TABLE 55 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA 121
TABLE 56 INDIA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 121
TABLE 57 INDIA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 122
TABLE 58 INDIA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 122
TABLE 59 REST OF WORLD STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 122
TABLE 60 SIGNIFICANT STEM CELL RESEARCH PATENTS 172

LIST OF FIGURES

SUMMARY FIGURE GLOBAL STEM CELL MARKET AND FORECASTS, 2012-2018 ($
MILLIONS) 8
FIGURE 1 EARLY DEVELOPMENT OF EMBRYO 10

To order this report: The Global Market for Stem Cells
http://www.reportlinker.com/p02274672/The-Global-Market-for-Stem-Cells.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, will examine the regulations and provide insight on how it affects technology, challenges the established rules and will usher in new levels of diligence a...
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
An increasing number of companies are creating products that combine data with analytical capabilities. Running interactive queries on Big Data requires complex architectures to store and query data effectively, typically involving data streams, an choosing efficient file format/database and multiple independent systems that are tied together through custom-engineered pipelines. In his session at @BigDataExpo at @ThingsExpo, Tomer Levi, a senior software engineer at Intel’s Advanced Analytics ...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that’s no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, will explore how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He wi...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
In the enterprise today, connected IoT devices are everywhere – both inside and outside corporate environments. The need to identify, manage, control and secure a quickly growing web of connections and outside devices is making the already challenging task of security even more important, and onerous. In his session at @ThingsExpo, Rich Boyer, CISO and Chief Architect for Security at NTT i3, discussed new ways of thinking and the approaches needed to address the emerging challenges of security i...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
There is only one world-class Cloud event on earth, and that is Cloud Expo – which returns to Silicon Valley for the 21st Cloud Expo at the Santa Clara Convention Center, October 31 - November 2, 2017. Every Global 2000 enterprise in the world is now integrating cloud computing in some form into its IT development and operations. Midsize and small businesses are also migrating to the cloud in increasing numbers. Companies are each developing their unique mix of cloud technologies and service...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.